Phospholipase A2-Induced Platelet Aggregation, Release and Lysis.

1979 ◽  
Author(s):  
D. Heinrich ◽  
S. Beckmann

Activation of washed platelets by exogenous phospholipase A2 (PIA2) purified from crotalus terrificus terrificus venom was studied. Platelets were labeled with 14C-serotonin and 51chromium and resuspended in Tyrode/albumin (TA). With 1-5 μg/ml (final conc.) of crotalus PIA2 no direct platelet alterations were observed. These platelets, however, were refractory to collagen - but not to thrombin or HLA-specific antibodies.10-50 μg/ml crotalus PIA2 rapidly induced platelet aggregation and release 100 μg/ml crotalus PIA2 induced platelet lysis.PIA2-induced platelet alterations were inhibited by EDTA, PGE1, ASS and apyrase. Crotapotin, an acid peptid isolated from crotalus venom, forms complexes with crotalus PIA2 and specifically inhibits PIA2-induced platelet alterations.Conclusion: PIA2-induced platelet alterations are due to liberation of arachidonic acid from phospholipids of the platelet membrane inducing prostaglandin and thromboxane synthesis. With high concentrations of PIA2 breakdown of membrane phospholipids will lead to platelet lysis.

1987 ◽  
Author(s):  
R S Labow ◽  
E Meek ◽  
G A Adams ◽  
G Rock

Arachidonic acid (AA) is liberated from platelet membrane phospholipids during stimulation and promotes cellular aggregation through the synthesis of thromboxane A2. Two pathways; phospholipase A2 (PLA2) or phospholipase C (PLC) followed by the action of acylglycerolipases, are thought to be activated during platelet stimulation and supply the necessary AA. We have reported that mono (2-ethylhexyl)phthalate (MEHP), a physiological metabolite of the plasticizer di(2-ethylhexyl)-phthalate (DEHP), commonly used in a variety of medical devices and storage containers, inhibits PLA2, but not PLC in platelet lysates. The effects of MEHP on intact platelets were studied. PLA2 activity in intact platelets or lysates was assayed by incubating them with 2-14C-arachidonyl-phosphatidylcholine and measuring formation of free 14C-arachidonic acid in 10 min. Platelet lysates hydrolyzed 10% of the substrate while 2.6% was hydrolyzed by intact platelets. The amount of MEHP needed to inhibit 14C-AA liberation was 0.35 mM for platelet lysates and 0.7 mM for intact platelets. Platelet aggregation induced by collagen was inhibited by MEHP (1 mM), although responses to adenosine diphosphate, AA and ionophore were unaffected. Identical effects on platelet aggregation were found when indomethacin (0.1 mM) was added. Higher concentrations of MEHP blocked platelet aggregation induced by adenosine diphosphate or AA but not ionophore or synergistic pairs of these stimuli, indicating a more generalized membrane disruption at higher MEHP concentrations. These results suggest that MEHP acts in a similar manner to indomethacin to block PLA2-mediated liberation of arachidonate during platelet aggregation(supported by MRC and NHRDP, Canada)


1981 ◽  
Author(s):  
J Suda ◽  
N Aoki

Platelet myosin light chain kinase is a calmodulin dependent enzyme which requires calmodulin for its activity and is intimately related to actomyosin contracting system. Platelet actomyosin contraction may cause the release reaction of platelet. N-(6-aminohexyl)-5-chloro-naphthalene sulfonamide (W-7) is one of the calmodulin interacting agents, and selectively inhibits calmodulin activity. Since platelet membrane phospholipases which are responsible for the release of arachidonic acid from membrane phospholipids may also be calmodulin-dependent enzymes, the inhibitory effects of W-7 on platelet function were examined. W-7 in a concentration as low as 10 7#x03BC;M inhibited platelet aggregation and release reaction induced by ADP, collagen, epinephrine, thrombin, arachidonic acid and Ca2+-ionophore A23187. When platelets were preincubated with W-7 before addition of an aggregating agent, the inhibition became more pronounced. In ADP-induced aggregation, only the second phase was inhibited. Arachidonate metabolites (PGG2/H2 and thromboxane A2) failed to induce aggregation and release reaction of platelets preincubated with W-7. Furthermore, release of arachidonic acid from platelet membrane phospholipids induced by A23187 in the presence of indomethacine was inhibited by W-7. W-7 had no effect on glucose metabolism in platelets. The c-AMP levels in platelets were not significantly changed by incubation with W-7. These results suggest that W-7 inhibits directly phospholipase A2 and/or phospholipase C in addition to myosin light chain kinase. These results may in turn indicate that calmodulin is involved in platelet aggregation and release reaction mechanism including membrane phospholipases and the target system of thromboxane A2 (possibly actomyosin contracting system).


1988 ◽  
Vol 59 (03) ◽  
pp. 383-387 ◽  
Author(s):  
Margaret L Rand ◽  
Marian A Packham ◽  
Raelene L Kinlough-Rathbone ◽  
J Fraser Mustard

SummaryEthanol, at physiologically tolerable concentrations, did not affect the primary phase of ADP-induced aggregation of human or rabbit platelets, which is not associated with the secretion of granule contents. Potentiation by epinephrine of the primary phase of ADP-induced aggregation of rabbit platelets was also not inhibited by ethanol. However, ethanol did inhibit the secondary phase of ADP-induced aggregation which occurs with human platelets in citrated platelet-rich plasma and is dependent on the formation of thromboxane A2. Inhibition by ethanol of thromboxane production by stimulated platelets is likely due to inhibition of the mobilization of arachidonic acid from membrane phospholipids, as ethanol had little or no effect on aggregation and secretion induced by arachidonic acid or the thromboxane mimetic U46619. Rabbit platelet aggregation and secretion in response to low concentrations of collagen, thrombin, or PAF were inhibited by ethanol. Inhibition of the effects of thrombin and PAF was also observed with aspirin-treated platelets. Thus, in addition to inhibiting the mobilization of arachidonate for thromboxane formation that occurs with most agonists, ethanol can also inhibit aggregation and secretion through other effects on platelet responses.


1987 ◽  
Author(s):  
J Kienast ◽  
J Arnout ◽  
G Pfliegler ◽  
H Deckmyn ◽  
B Hoet ◽  
...  

Elevated cytosolic free Ca2+ concentrations ([Ca2+]i) are thought to be required for phosphol ipase A2 activity to liberate arachidonic acid (AA) from membrane phospholipids in platelets. The major AA metabolite formed during agonist-induced platelet activation is thromboxane A2 (TxA2). We have investigated the effect of sodium fluoride (NaF) on platelet TxAz formation in correlation to platelet functional changes (aggregation and release of ATP) and intracellular events specific for either agonist- or antagonist-induced platelet responses. A first peak in platelet TxAffi formation reaching 30 × control values was observed at 20 - 30 mM of NaF which also induced platelet aggregation and release of ATP in association with a rise in [Ca2+]i . Increasing the concentration of NaF resulted in a decrease in TxA2 release to a minimum of 12 × control values at 50 mM. A second, concentration-dependent rise in TxA2 formation was observed at higher concentrations of NaF with a maximum of 40 × control values at 100 mM. These concentrations, however, did induce neither aggregation nor a significant rise in [Ca2+]i but a rapid, transient increase in platelet cAMP levels. Activation of phospholipase C and protein kinase C was observed at all concentrations of NaF tested whereby the rate rather than the extent of activation of these enzymes was concentration-dependent. Our results demonstrate that fluoride at high concentrations can induce platelet TxA2 formation in the absence of elevated [Ca2+]i suggesting an additional, Ca2+-independent mechanism of phospholipase A2 activation possibly mediated by fluoride sensitive GTP-binding regulatory proteins.


1981 ◽  
Author(s):  
M Cattaneo ◽  
R L Kinlough-Rathbone ◽  
J F Mustard

In contrast to other release-inducing agents (e.g. thrombin) arachidonic acid (AA) releases only 40-50% of amine storage granule contents and although low concentrations induce aggregation, high concentrations do not. Several theories have been proposed to explain these observations: 1) AA or its products inactivates the cyclo-oxygenase; 2) the products of AA increase platelet cAMP; 3) lipoxygenase products are inhibitory; 4) unsaturated fatty acids (UFA) perturb the cell membrane. Using washed rabbit platelets we examined the effect of AA on platelet function. In these experiments aspirin-treated platelets (ASA 5.5 mM) were exposed to AA (230 μM) for 15 min. and then to PGEj (10 μM) for 30 min. The platelets were then resuspended. These platelets did not aggregate to ADP (9 μM) and their response to thrombin (0.02-0.05 U/ml) was impaired in contrast to control, ASA-treated platelets not exposed to AA. Non-ASA-treated platelets exposed to AA (230 μM), deaggre- gated with PGE1, and then resuspended also did not aggregate in response to ADP (9 μM) collagen, AA (230 μM) or thrombin (0.02-0.05 U/ml). When platelets pretreated with ASA and AA were mixed 1:1 with normal platelets and the mixture stimulated with AA (230 μM), the AA-treated platelets did not release their granule contents whereas the normal platelets did. These results do not support the hypothesis- that the inhibitory effect of AA on platelet aggregation and release is primarily due to inhibition of cyclo-oxygenase or an increase in cAMP caused by AA products. It seems unlikely that inhibition by AA can be due to products of the lipoxygenase pathway, because the effect persists when the platelets are washed and resuspended. Similar results were obtained by incubating platelets with linoleic acid (230 μM). This evidence is compatible with the hypothesis that UFA can inhibit platelet function by perturbing the cell membrane. This effect may be related to changes in receptor availability.


1985 ◽  
Vol 68 (4) ◽  
pp. 449-454 ◽  
Author(s):  
John H. Galloway ◽  
Ian J. Cartwright ◽  
Barrie E. Woodcock ◽  
Michael Greaves ◽  
R. Graham ◽  
...  

1. The fatty acid composition of membrane phospholipids of stimulated and unstimulated platelets was studied in six normal volunteers given a daily dietary supplement of a fish oil rich in eicosapentaenoic acid (EPA) for 4 weeks. The supplement was equivalent to 1.8 g of EPA daily. Thromboxane synthesis and platelet aggregation responses to sodium arachidonate, thrombin and the ionophore A23187 were also investigated. 2. A marked increase in the relative EPA content of phosphatidylcholine (PC) and phosphatidylethanolamine (PE) was noted after 2 and 4 weeks fish oil supplementation. However, there was no incorporation into phosphatidylinositol (PI) or phosphatidylserine (PS). The relative arachidonic acid (AA) content of PC and PE was significantly reduced at 2 and 4 weeks but that of PI and PS remained unchanged. Significant reductions in the relative linoleic acid content of total phospholipids, PC and PE were also noted. 3. Stimulation of platelets obtained after 4 weeks fish oil supplementation by thrombin and A23187 was associated with a marked reduction in the AA content of PI and a minor reduction in that of PE. There was no change in the relative proportions of EPA in PI, PS, PC or PE after stimulation. Throughout the study there were no significant changes in platelet aggregation responses or in platelet thromboxane production. 4. Our results indicate that the incorporation of EPA into the platelet membrane phospholipids is selective and that if PI is the major source of AA for platelet prostaglandin biosynthesis then the reported beneficial effects of EPA on haemostasis cannot be explained on the basis of its incorporation into and mobilization from the platelet membrane phospholipid pool.


Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 3892-3892
Author(s):  
Shogo Kasuda ◽  
Yoshihiko Sakurai ◽  
Midori Shima ◽  
Masahiro Takeyama ◽  
Katsuhiko Hatake ◽  
...  

Abstract Background: Moderate consumption of alcohol beverages reduces the morbidity from coronary heart disease. Previous studies describing of inhibitory activity of ethanol (EtOH) on platelet function have substantiated this observation. However, the effects of EtOH on thrombin-related platelet activation remains to be fully elucidated, though platelet activation by thrombin is essential for normal hemostasis as well as relevant to pathophysiological conditions of thrombosis. Objectives: The aim of this study is to elucidate the effect of EtOH on α-thrombin-related platelet function by measuring platelet aggregation and intracellular calcium ([Ca2+]i). Materials and Methods: A dual-wavelength spectrofluorometer was used for measurement. α-thrombin, PAR1-activating peptide (AP) (10 μM) or PAR4-AP (25 μM) was added to fura2-AM loaded washed platelet preincubated with or without EtOH (40, 80, 160 and 320 mM). Results and Interpretations: First, the effects of EtOH on 0.5 nM of thrombin-induced platelet activation was assessed. The concentration 0.5 nM used is conceived to activate platelets only via PAR-1. EtOH did not affect platelet aggregation. EtOH inhibited rise of [Ca2+]i dose-dependently. [Ca2+]i peak time at which maximal rise of [Ca2+]i delayed in a dose-dependent manner. Secondly, 10 nM of thrombin was used as an agonist. Stimulation by high concentrations of thrombin (〉 5nM) results in cleavage of both PAR1 and PAR4. The changes in [Ca2+]i showed double-phase curve composed of transient spike and prolonged peak in the absence of EtOH. Although EtOH inhibited neither platelet aggregation nor the first phase of [Ca2+]i increasing, it reduced the second prolonged elevation of [Ca2+]i dose-dependently. To elucidate the inhibiting mechanism of EtOH more precisely, the effects of EtOH on PAR1-AP-induced platelet function were examined. Rise of [Ca2+]i gave a spike form and was almost unchanged even in the presence of high concentrations of EtOH, whereas platelet aggregation was reduced and dissociated in the presence of EtOH. Lastly, the effects of EtOH on PAR4-AP-induced platelet function was examined. Aggregation of PRP was quenched by high concentrations of EtOH but dissociation was not observed contrary to that observed in PAR1-AP-induced aggregation. Further, EtOH inhibited [Ca2+]i rise and delayed [Ca2+]i peak time dose-dependently. Our results provided a possible mechanism by which EtOH inhibits platelet activation. Reduction of the prolonged elevation of [Ca2+]i by high concentrations of thrombin suggested that EtOH inhibits PAR4 signaling not PAR1 since the second prolonged phase of [Ca2+]i is mediated by PAR4. Inhibition of PAR4-induced aggregation and [Ca2+]i elevation by EtOH supported the findings and EtOH might reduce Ca2+ influx through inhibition of PAR4. Furethermore, the difference between the platelet activation mechanisms of low concentrations of thrombin and PAR1-AP was suggested. PAR1-AP can aggregate platelets at least but might fail to activate phospholipase A2 required for sustaining stable aggregation since EtOH abolishes phospholipase A2 and thereby reduces thromboxane A2 generation. On the other, thrombin at low concentrations might have another pathway for activating platelet differently than PAR1-AP. Further characterization of the mechanisms involved in inhibition of platelet activation by EtOH may help develop new strategies to control thrombin-mediated platelet activation.


Blood ◽  
1998 ◽  
Vol 91 (2) ◽  
pp. 484-490 ◽  
Author(s):  
Pasquale Pignatelli ◽  
Fabio M. Pulcinelli ◽  
Luisa Lenti ◽  
Pier Paolo Gazzaniga ◽  
Francesco Violi

Abstract In this study, we investigated whether (1) collagen-induced platelet aggregation is associated with a burst of H2O2, (2) this oxidant species is involved in the activation of platelets, and (3) the pathways of platelet activation are stimulated by H2O2. Collagen-induced platelet aggregation was associated with production of H2O2, which was abolished by catalase, an enzyme that destroys H2O2. H2O2 production was not observed when ADP or thrombin were used as agonists. Catalase inhibited dose-dependently thromboxane A2 production, release of arachidonic acid from platelet membrane, and Inositol 1,4,5P3 (IP3) formation. In aspirin-treated platelets stimulated with high concentrations of collagen, catalase inhibited platelet aggregation, calcium mobilization, and IP3 production. This study suggests that collagen-induced platelet aggregation is associated with a burst of H2O2 that acts as a second messenger by stimulating the arachidonic acid metabolism and phospholipase C pathway.


1981 ◽  
Author(s):  
M Rigaud ◽  
H Rabinovitch ◽  
J Durand ◽  
J C Breton ◽  
G Rigaud

When ticlopidine is added to macrophages cultures, in the absence of exogenous arachidonic acid, there is a production of both“prostanoids” and“eicosanoids” in the culture medium. These products have been measured using glass capillary gas chomatography prior to multiple ion mass spectrometry. The quantitative determinations are made 5, 15, 25, 35 and 45 minutes after the drug was added to the macrophages cultures. The three drug concentrations used (10-4M, 5.10-5M and 2.5 10-5M) induce a liberation of 6-keto-PGF1α in the culture medium. As in our system 6-keto-PGF1α seems to be the major metabolite of PGI2, ticlopidine is likely to act by releasing important quantities of PGI2 in macrophages. These results suggest an increase of liberation of the endogenous arachidonic acid from the membrane phospholipids of the macrophages or a lack in the acyltransferase system of the cell membranes. The lipoxygenasic pathway was also studied. When ticlopidine is added to macrophages, two products are liberated: . 12-HETE as measured by single iondetection . and 10-hydroxy-ll-12-epoxy, -5, 8, 14-eicosatrienoic acid which comes from an internal rearrangement of the 12-HPETE. In these results, there is a discrepancy between the fact that ticlopidine increases the concentration of 12-HETE and surely its precursor the 12-HPETE and the fact that the synthesis of PGI2 is not inhibited by these high concentrations of hydroperoxide. To understand this phenomenon we studied the production of hydroperoxide when arachidonic acid is incubated with soybean lipoxygenase. When ticlopidine (10-4M) is added to the reaction mixture (AA + soy lipoxygenase) there is an increase of the initial rate and an extent of the reaction as if the enzyme irreversible deactivation was postponed. Ticlopidine could act by suppressing the classical inhibition of PGI2 synthetase by hydroperoxides, in particular 12-HPETE and 15-HPETE, both produced by mammalian cells.


Development ◽  
1994 ◽  
Vol 120 (6) ◽  
pp. 1685-1693 ◽  
Author(s):  
E.J. Williams ◽  
J. Furness ◽  
F.S. Walsh ◽  
P. Doherty

Cerebellar neurons, cultured on monolayers of 3T3 fibroblasts or on a polylysine/laminin-coated substratum, responded to recombinant basic FGF by extending longer neurites. The response was biphasic reaching a maximum at 5 ng/ml FGF, but desensitising at 100–200 ng/ml FGF. The response to FGF could be inhibited by a tyrosine kinase inhibitor (the erbstatin analogue), by a diacylglycerol lipase inhibitor (RHC-80267) and by a combination of N- and L-type calcium channel antagonists or other agents that negate the effects of calcium influx into neurons. The response to FGF could be fully mimicked by arachidonic acid added directly to the cultures, or generated via activation of phospholipase A2 with melittin. The response to melittin, but not to FGF or arachidonic acid, was inhibited by 4-bromophenacyl bromide, a phospholipase A2 inhibitor. The response to arachidonic acid was also biphasic and high concentrations of this agent could cross-desensitise the FGF response and vice versa. The response to arachidonic acid could be fully inhibited by the agents that block or negate the effects of calcium influx into neurons, but was not inhibited by the tyrosine kinase or diacylglycerol lipase inhibitors. These data suggest that FGF stimulates neurite outgrowth by activating a cascade that involves activation of phospholipase C gamma to produce diacylglycerol, conversion of diacylglycerol to arachidonic acid by diacylglycerol lipase and the activation of voltage-gated calcium channels by arachidonic acid.


Sign in / Sign up

Export Citation Format

Share Document